Drug Profile

Sibutramine/Topiramate - Eurofarma

Alternative Names: Sibutramine/Topiramate

Latest Information Update: 28 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eurofarma
Class Cyclobutanes; Dioxolanes; Hexoses; Ketoses; Obesity therapies; Pyrans; Small molecules; Sulfonic acids
Mechanism of Action GABA A receptor agonists; Serotonin uptake inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Mar 2026 No recent reports of development identified for preclinical development in Obesity in Brazil (PO, Capsule)
01 Feb 2022 Preclinical trials in Obesity in Brazil (PO) (Eufarma website,
01 Feb 2022 Eurofarma plans a phase III trial for Obesity in Brazil (In adults) (NCT05209984)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com